Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bobby,
Please accept my condolences. Many stories similar to yours and all of us hope that NWBO will be instrumental in combating this insidious disease.
Question for the MB: NWBO’s CDMO, Cognate BioServices… is there an approximate date when Advent BioServices might be operational; and, what about the proposed manufacturing facility at Johns Hopkins University?
LessisMore….
I think you may be interested in reading this article:
At the beginning of the year, Larry Fink, CEO of BlackRock, sent out a letter to the CEO’s of major companies. Andrew Ross Sorkin of CNBC Squawk Box and NY Times
published a piece regarding the letter - here is Andrew’s article entitled: “BlackRock’s Message: Contribute to Society, or Risk Losing Our Support”
https://www.nytimes.com/2018/01/15/business/dealbook/blackrock-laurence-fink-letter.html
Thank you Flipper, for the additional information.
Recently noted - A “call for manuscripts” by MDPI ( peer-reviewed, open access journal) located in Basel, Switzerland. Are open access journals primarily for the academic world as opposed to publications like NEJM, Lancet, and the like? Incidentally, I did notice an immunology physician from UCLA on MDPI’s Editorial Board.
“Special Issue "Therapeutic Vaccines and Cancer Immunotherapy"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 May 2018”
http://www.mdpi.com/journal/vaccines/special_issues/therap_vaccines_cancer_immunotherapy
Has this new 8K been posted
8K Filing
https://www.sec.gov/Archives/edgar/data/1072379/000114420418024749/0001144204-18-024749-index.htm
Add my thank you to the tab, Beartrap
AV ….Fair enough
Raconteur’s Report is apparently considered an advertising piece as its purpose states in part:
“ With topics ranging from business and finance to technology and healthcare, Raconteur’s reports offer highly targeted marketing and communications opportunities in a medium which is proven to drive engagement and call to action from its readership.”
https://www.gov.uk/government/publications/advertising-investigations-august-2015/24-august-2015-advertising-an-unlicensed-medicine
I’m not quite sure what details were involved in the management buyout. Hope one of our financial gurus can chime in. But, yes, BlackRock is the leader in investment firm standings.
I don't know what to make of that. Did you get the entire announcement?
It can be accessed directly from Tennenbaum’s website:
News & Events
BlackRock, Inc. to Acquire Private Credit Manager Tennenbaum Capital Partners?April 17, 2018
Thanks! I knew you would like it….and wait, there’s more breadcrumbs to follow.
FYI: New job posting by Cognate (NWBO’s manufacturer of DCVax) If this has been posted previously, I did not notice.
The Director of Validation will be responsible for management and oversight of the Validation Program including the facility, equipment and methods for a Cell and Gene Therapy contract manufacturing facility. The facility currently supports multiple clients producing Phase 1, 2 and 3 clinical cell and gene therapy products and is anticipating manufacturing commercial products. The position will also be responsible for management of a team of validation specialists of varying experience levels
https://www.cognatebioservices.com/director-validation/
Acknowledged Marzan - Can’t forget Dr. Antoni Ribas, UCLA, who is receiving an award and it is Dr. Ribas who was instrumental in the development of Keytruda
Parker Institute PR - Cancer Vaccine presentation at AACR 4.14.2018
https://www.parkerici.org/2018/04/05/aacr18-parker-institute/
Perhaps the delay in peer review publication is advertising related - we are surmising that DC-Vax is a disruptive therapy and the expected article may not be compatible with other pharma ad campaigns. Are advertisers made aware of upcoming publication content enabling them to plan their ad placement and buys? How many pharma companies would chose not to place their ad/brand in the issue highlighting NWBO’s data.
“Is Content of Medical Journals Related to Advertisements? Case-control Study”
“Conclusions
The strong relatedness between the content of the articles and advertisements placed in 3 of 7 journals and explicit placement of the advertisements face to face or overleaf the related research articles support the hypothesis that journal content is manipulated to place more emphasis on the advertisements.”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213802/
Reminder: Dr. Scott Gottlieb is on CNBC’s “Investing in Healthcare Innovation” special this morning - starting at 9:00am. He will be interviewed by Meg Terrill.
https://www.cnbc.com/2017/11/08/healthy-returns.html#block3
Thank you, Flipper. A tough cancer to confront that’s for sure. I should hope NWBO’s anticipated successful data comes into the light very soon.
VBL Therapeutics - Late-stage study failure
https://www.firstwordpharma.com/node/1547414?tsid=28®ion_id=6
…..et cum spiritu tu wa
AstraZeneca spins off new biotech company
https://health.economictimes.indiatimes.com/news/pharma/astrazeneca-spins-off-autoimmune-drugs-into-new-biotech-company/63110408
A heart-lifting article about a recently approved drug for adults being administered to an 8-year old child to save his life as the last minutes were ticking away:
https://www.firstwordpharma.com/node/1545080?tsid=28®ion_id=4